Gottlieb Closing In On Confirmation Despite Senate Concern On Opioids
US FDA commissioner nominee clears procedural hurdle as agency's opioid policy remains a charged political issue.
You may also be interested in...
A former Walmart executive will replace the deputy commissioner for foods and veterinary medicine, who spent nearly 15 months total as acting commissioner.
US FDA is moving forward on two fronts to update and improve the Risk Evaluation & Mitigation Strategy to help limit misuse and abuse of opioid pain medications: the agency has a plan to incorporate IR sponsors into the existing REMS, and also a new 'blueprint' for the prescriber education that focuses on pain management.
New FDA Commissioner tells employees that 'too many consumers are priced out of medicines they need' and that FDA must take meaningful steps to get lower cost alternatives to market.